Genome Institute of Singapore, Johns Hopkins Ink Deals with Illumina
Illumina announced two separate genotyping deals with the Genome Institute of Singapore and Johns Hopkins University last week that will give researchers at both organizations access to its BeadChip technology.
According to Illumina, the Genome Institute of Singapore will use Illumina's BeadChip technology to analyze 3,000 samples.
The Institute will work with an undisclosed pharmaceutical company in a collaboration using Illumina’s HumanRef-8 Expression BeadChip. An Illumina spokesperson declined to name the company in an e-mail, but revealed that it was a new pharma customer. Illumina has disclosed deals with Merck and GlaxoSmithKline in the past (see BAN 7/5/2006). Financial terms of the agreement were not disclosed.
Separately, Illumina said last week that Johns Hopkins Medical School will use its BeadChip tool as part of a large asthma study.
Johns Hopkins researchers and colleagues from the National Human Genome Center at Howard University will use Illumina’s Infinium HumanHap650Y to identify genes related to asthma in a study that will include 2,000 individuals and their families, the company said.
The study will focus on African-American and African-Caribbean volunteers. Illumina CEO Jay Flatley said in a statement that this particular BeadChip technology is designed for studying African populations.
Some genes have already been linked closely to asthma, the company said, but a comprehensive analysis has not been specifically aimed at studying African populations.
The results from this study will be compared with those of a similar study in England, and with data from an ongoing Yale University study of asthma in European ancestry.
The study is funded by the National Heart, Lung and Blood Institute and the NIH and the National Institutes of Health.
Financial terms of either deal were not disclosed.
Agendia Names MammaPrint Distributor for Argentina, Paraguay
Agendia last week said it has given Argentine distributor Teva & Tutor exclusive rights to market Agendia's MammaPrint microarray-based breast cancer prognostic in Argentina and Paraguay.
Agendia, based in the Netherlands, said that the South American expansion is part of a larger global sales effort, and said this is "an important step in opening more markets."
Financial terms of the agreement were not released.
Agilent Opens Product Demo Centers in California, India
Agilent Technologies this week opened product demo facilities in the US and India, the company said last week.
Agilent opened a 5,000-square-foot product-demonstration center today in Santa Clara, Calif., to exhibit its liquid and gas chromatography systems, mass-spec systems, and microarray scanners. The facility also holds labs designed for proteomics and genomics, a wet lab, and conference spaces.
The company said it opened a similar center in Bangalore, India, on Monday to add to others it has opened in France, the UK, and Germany.
Agilent said it plans to open another demo facility in Little Falls, Del., in 2007 (see BAN 6/20/2006).
Chris van Ingen, Agilent’s president of Life Sciences and Chemical Analysis business, said the centers “provide a one-stop customer experience highlighting our entire portfolio of products and services.”
CXR Licenses Rosetta’s Resolver System
CXR Biosciences has licensed Rosetta Biosoftware’s Resolver system, Rosetta said this week.
CXR, a Dundee, Scotland-based drug developer, said it will use the software to determine the toxicological profiles of early-stage compounds in microarray-powered drug -toxicity studies.
Financial terms of the deal were not released.